About us

At Fidelta, we are driven to provide high quality drug discovery services and solutions to our clients. We have the necessary set up and expertise for fully integrated drug discovery, backed up by a successful delivery track record. Choose from a range of stand-alone services or let us customize a service package to meet your specific needs in drug discovery. We are driven to provide high quality drug discovery services and solutions to our clients, and we strongly believe that building long-term relationships with our clients is the key to mutual success and satisfaction. We pride ourselves in working through close communication with our clients, flexibility, problem solving orientation and delivery within agreed timelines.

Our values

Our values

Fidelta’s objective is to deliver efficacious, safe, and differentiated pre-clinical candidates for its clients. Our mission is clear: we are working together to create research solutions that will have an impact on patients’ lives. We provide comprehensive, integrated drug discovery services to deliver solutions for our partners as quickly as possible through the highest quality science, know-how, expertise, and operational excellence.

People

People photo
160+ scientists
12+ years of experience
38% holds a PhD degree
65+ patents
250+ publications
Almost 40% of our scientists hold PhDs in various disciplines, covering:
Chemistry
Biology
Pharmacy
Medicine
Veterinary medicine
Fidelta is an equal opportunities employer

Executive Management

  • Adrijana Vinter,<br>PhD, MBA

    Adrijana Vinter,
    PhD, MBA

    Managing Director

    Adrijana Vinter, became Managing Director in Jan 2017. She Obtained her PhD in Chemistry at the University of Zagreb in the field of new macrolide antibiotics. She started her career in PLIVA in 2002 working initially as a scientist and then obtained an MBA at Cotrugli Business School, Croatia before moving to Business Development on the creation of Fidelta. She has successfully engineered and overseen the development of the Fidelta revenue stream resulting in significant year on year growth. She is the co-author of several scientific papers and patent.

  • Marija Gradečak Galović,<br>ACMA, CGMA

    Marija Gradečak Galović,
    ACMA, CGMA

    Head of Finance

    Ms. Gradečak Galović is a Chartered Management Accountant and holds a Master Degree in business administration (University of Zagreb). She joined GSK in 2007 as Finance analyst prior to becoming Finance Manager DPU Macrolide in 2009. Ms Gradečak Galović has held her current position since 2010. Prior to joining GSK, she spent five years as a Management Accountant in Unilever Croatia.

  • Steve Price, PhD

    Steve Price, PhD

    VP Chemistry and DMPK

    Steve has over 24 years of experience working in drug discovery contract research organisations. He spent the first 5 years of his career as a medicinal chemistry project leader at Evotec before joining Argenta (now Charles River Discovery) where he held several senior positions, including Managing Director and Executive Director of Chemistry. Steve has led more than 40 medicinal chemistry collaborations with large pharma, biotech and virtual organisations. These collaborations have involved the majority of druggable target classes, spanning multiple therapeutic areas (including oncology, anti-infective, respiratory, inflammation, pain), and delivering over 20 development candidates for which more than 10 have entered the clinic. Previous to his CRO experience Steve spent a short spell as a process chemist at Glaxo-Wellcome after obtaining his BSc and PhD in medicinal chemistry from the University of Manchester (formerly UMIST). He is an inventor, author or co-author on over 80 patents and publications.

  • Vesna Eraković Haber,<br>MD, PhD, MBA

    Vesna Eraković Haber,
    MD, PhD, MBA

    VP Pharmacology and Translational Research

    Dr. Vesna Eraković Haber holds a medical degree and a PhD in biomedical sciences and pharmacology (Medical School, University of Rijeka, Croatia), as well as an MBA degree (IEDC Bled School of Management, Slovenia). She has been working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos, as well as Fidelta, for the last 22 years holding several leading R&D positions including Director of Drug Discovery and Director of Research in PLIVA, Director of Biology in GSK and VP Biology in Galapagos. Her work, focused mainly on anti-infective and anti-inflammatory research has contributed to the progression of several drug discovery projects and resulted in more than 70 peer reviewed publications and patent applications. She is Professor at the Department of Biotechnology and Department of Pharmacology, Medical Faculty, University of Rijeka.

  • Jasna Padovan, PhD

    Jasna Padovan, PhD

    Head of DMPK

    Jasna has extensive experience in preclinical ADME/PK and regulated bioanalysis, with over 23 years in drug discovery. She worked in different positions within pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos, mainly in therapeutic areas of infection and inflammation. Jasna obtained a degree in biochemistry from the University of Colorado Boulder, was trained in PK/PD within the Leiden/Amsterdam Centre for Drug Research and obtained her PhD in Analytical Chemistry from the University of Zagreb, as well as an MBA degree from Cotrugli Business School (Croatia). During her career she has worked on projects which have delivered seven development candidates, is author or co-author on over 15 publications and has presented at several international conferences.

  • Ines Glojnarić, PhD

    Ines Glojnarić, PhD

    Head of In vivo Pharmacology
    and Toxicology

    Dr. Ines Glojnarić obtained her PhD in Medical biochemistry. Since 1994 she has been working in pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos holding several leading positions including Director of Pharmacology and Medicinal Safety at PLIVA, responsible for preclinical toxicity assessment, pharmacodynamics, pharmacokinetics and drug metabolism. During her career, she has worked on projects across multiple therapeutic areas (infection, inflammation and autoimmune, respiratory, fibrosis) which have delivered seven development candidates, three of which have reached at least Phase I in the clinic. She has published 28 scientific publications and has presented at several international conferences. She has obtained several certificates in the field of pharmacology, good laboratory practice and management in pharmaceutical industry.

  • Darko Marković, DVM, PhD

    Darko Marković, DVM, PhD

    Director of Toxicology and LAS

    Dr.sc. Darko Marković holds a veterinary medicine degree, master/spec. in veterinary medicine and PhD in biomedicine and health/toxicology. He obtained several certificates in various fields including Toxicology, Pharmacology, Laboratory Animal Science (LAS) and GLP. He joined PLIVA in 1993 (spent a year at Parke/Davis, USA), were he held several positions in R&D including Head of Toxicology WU (PLIVA) and Director of Laboratory Animal Science within GlaxoSmithKline (2007-2010). As part of his portfolio within GSK, an Ethics Committee was established and local Animal Facility obtained AAALAC accreditation. In 2010, within Galapagos (Fidelta d.o.o.), he was appointed to position of Director- Toxicology & Laboratory Animal Science, having an overall responsibility for Toxicology, as well as for the Animal Facility (AAALAC, OLAW accreditation) and all Laboratory Animal Science work/issues (courses in LAS accredited under the FELASA „Categories system“). In 2021, within Fidelta d.o.o. (Selvita Group), he was appointed to his current position (Toxicology & Laboratory Animal Science, Director) with an overall responsibility for Toxicology, as well as the Animal Facility and all Laboratory Animal Science work/issues. His portfolio encompasses conduct of all in vivo research activities and compliance with national and international regulatory agencies rules and international standards. During his career he has worked on projects which have delivered seven development candidates. He has over twenty-eight years’ experience in the Pharmaceutical industry, has over 20 scientific publications and has presented at several international conferences. As a Lecturer is teaching at the University (field Toxicology and Laboratory Animal Science).

  • Martina Bosnar, PhD

    Martina Bosnar, PhD

    Head of In vitro pharmacology

    Martina Bosnar has a degree in molecular biology and a PhD in biology. She started her career in 2001 working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos where she has been advancing through positions of increasing responsibilities. Her work focused mainly on anti-inflammatory research. During her career she has contributed to progression of several drug discovery projects. She has authored over 20 scientific publications, has presented at several international conferences and is an inventor on 3 patents.

  • Sulejman Alihodžić,<br>PhD

    Sulejman Alihodžić,
    PhD

    Head of Chemistry

    Dr. Sulejman Alihodžić obtained his PhD in the field of chemistry. He conducted two years of postdoctoral research, awarded by the Robert A. Welch Postdoctoral Research Fellowship, at the University of North Texas. Sulejman started his career in 1998 working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos holding several leading positions including Head of Chemistry (GSK) and Director of Translational Chemistry (Galapagos) prior to taking his current position at the beginning of 2019. With 23 years of experience in the pharmaceutical industry and in the drug discovery contract research organization, Sulejman is an expert in medicinal chemistry, especially in the areas of antibacterial, antimalarials and anti-inflammatory drugs. This is complemented by his extensive experience in scale-up and physico-chemical profiling of NCEs. During his career, he has worked on projects delivering five development candidates, published over 50 scientific papers and holds 25 patents and patent applications.

  • Milan Mesić, PhD

    Milan Mesić, PhD

    Project Director, Chemistry

    Milan is responsible for leading interdisciplinary projects and collaborations with customers on different levels. His role is also to advise other Fidelta’s project leaders in scientific and customer communications.
    Milan has over 24 years of experience working in drug discovery. He obtained his PhD degree in chemistry and finished his postdoctoral research at Wake Forest University, NC, USA. Milan continued his industry career working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline, Galapagos and Fidelta focused mainly on anti-inflammatory, cancer, CNS and cardiovascular projects assuming the lead chemist, head of chemistry and project leader roles. During his career he has worked on projects which have delivered several clinical candidates, one of which has reached Phase II. He has authorship on over 44 patents and on over 37 scientific publications and has presented research work at several international conferences. He is Professor at the Department of Biotechnology, University of Rijeka and Medical Faculty, University of Osijek and Board Member of The Croatian Science Foundation.

  • Sanja Koštrun, PhD

    Sanja Koštrun, PhD

    Group Leader, CADD

    Dr. Sanja Koštrun graduated in chemistry and obtained her PhD in the field of computational chemistry. She had several short-term post-doctoral positions at the University of Innsbruck, the University of Florida, Sussex University, and a one year post-doc Humbolt fellowship at the University of Marburg. Sanja has been working in the pharmaceutical and biotech companies PLIVA, GlaxoSmithKline and Galapagos for the last 20 years. Throughout her industrial career, she has headed the Molecular modelling group, actively participating in a number of medicinal chemistry tasks and leading integrated projects in the anti-infective, anti-inflammatory, CNS and metabolic therapeutic areas. She published 40 scientific papers and two patent applications.

  • Dawid Radziszewski,<br>LLM

    Dawid Radziszewski,
    LLM

    Management Board Member

    Dawid Radziszewski is the General Counsel and Management Board Member at Selvita. He is in charge of all legal matters, including in particular complex corporate issues, IP licensing transactions, as well as a corporate development of the Selvita Group. As a Management Board member, he is additionally responsible for Group’s activity in the field of mergers & acquisitions.

  • Dariusz Kurdas

    Dariusz Kurdas

    Management Board Member

    Dariusz Kurdas is the Financial Director and Management Board Member at Selvita. He is in charge of all the financial and operational activities at Selvita Group. Dariusz is a registered Public Certified Auditor and licensed stockbroker.

person_1

History

Fidelta Team
1952

Fidelta established. The company originates from the Research Institute of PLIVA, where the blockbuster antibiotic azithromycin, later licensed to Pfizer, was discovered. The research focus of the PLIVA Research Institute was on therapeutic areas of infection and inflammation, and the group was well recognized within the scientific community for its leading role in macrolide chemistry.

2006

Acquisition of the PLIVA Research Institute by GlaxoSmithKline – the key driver was the company’s hands-on expertise in macrolide research. Within GSK, the Zagreb R&D site was set up as the Centre of Excellence in Macrolide Drug Discovery. It was later reorganized into the Macrolide DPU (discovery performance unit) and the Integrated Research Unit (IRU). While the Macrolide DPU pursued an internal portfolio of macrolide projects, the IRU offered integrated drug discovery services to other GSK DPUs, working across various therapeutic areas.

2010

The Galapagos group acquired the Croatia-based GSK R&D site. Within Galapagos, the company initially operated as an internal R&D service unit, providing support to several discovery and development projects, in addition to being fully responsible for the progression of an internal drug discovery project portfolio. The company has later become oriented towards external clients, offering drug discovery services to the pharmaceutical and related industries. To mark this change in the operating model, the company name was switched to Fidelta.

2021

Fidelta becomes a part of the Selvita Group. Fidelta is now fully consolidated under the Selvita Group. However, it continues to operate under the Fidelta name. The acquisition strengthens its presence in the preclinical CROs market and opens new growth opportunities. Bringing together these two companies allows Fidelta to keep a high level of quality and offer an even more integrated approach in services providing to the clients.

Facilities

Fidelta Zagreb
7500 square meters
State-of-art R&D facility
75 fume cupboards
20L reactors

Fidelta operates on four floors of a modern, state-of-the-art R&D facility occupying roughly 7500 square meters of laboratory and office space. The facility is fully equipped for drug discovery and development, including:

  • Chemistry laboratories with more than 75 fume cupboards,
  • A scale-up lab with up to 20 L reactors and a 4 L hydrogenation autoclave,
  • State of the art analytical equipment supporting chemistry and DMPK,
  • In vitro pharmacology labs set up for Biochemical assays, Cell based assays, Compound screening and Translational research,
  • An AAALAC and OLAW accredited facility for in vivo studies,
  • GLP certified bioanalysis.